Tumor mutational burden as a predictor of immunotherapy response in breast cancer

Tumor mutational burden (TMB) is a promising tool to help define patients with triple-negative breast cancer (TNBC) most likely to benefit from immune checkpoint blockade (ICB) therapies. Roughly reflecting the degree of neo-antigens that tumors present to immune cells, TMB associates with multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Meara, Tess A., Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939529/
https://www.ncbi.nlm.nih.gov/pubmed/33747355
http://dx.doi.org/10.18632/oncotarget.27877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939529/
https://www.ncbi.nlm.nih.gov/pubmed/33747355
http://dx.doi.org/10.18632/oncotarget.27877

Ejemplares similares